The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


87/5/9 Mcg/Dose Pressurised inhalation, solution

Chiesi Farmaceutici S.p.A.EU/1/18/1275/001-005

Main Information

Trade NameRiarify
Active SubstancesFormoterol fumarate dihydrate
Strength87/5/9 Mcg/Dose
Dosage FormPressurised inhalation, solution
Licence HolderChiesi Farmaceutici S.p.A.
Licence NumberEU/1/18/1275/001-005

Group Information

ATC CodeR03AL Adrenergics in combination with anticholinergics
R03AL09 Formoterol, Glycopyrronium Bromide and Beclometasone


Licence Issued23/04/2018
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back